FTSE 100 news / Companies and sectors / Pharma and healthcare / 12 October 2026
Pharma and healthcare: sector news on Monday 12 October 2026
Average tone +5.4 (positive) across 4 companies with relevant coverage, from 18 stories.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | −0.3 | 8 | Coverage was split between disappointing trial news, with ALXN1850 missing statistical significance and efzimfotase alfa missing its primary endpoint, and more positive stories about the $2 billion Summit investment and AI drug discovery. |
| GSK | +8.0 | 8 | Coverage centred on GSK's $800 million-plus expansion in Pennsylvania's Montgomery County, with over 300 new jobs and biologics manufacturing. |
| Convatec | +7.0 | 1 | Coverage focused on Convatec's Accelerate strategy, which is described as setting out a path to faster organic growth. |
| Smith & Nephew | +7.0 | 1 | Coverage focused on Smith & Nephew's launch of a cartilage implant in Europe, which is described as strengthening its sports medicine growth. |
| Haleon | – | 0 |
Strongest stories in the sector
- +10.0 Pennsylvania Governor announces $800M investment from GSK in biopharma hub
$800M US investment in biopharma hub announced. - +9.7 GSK Commits Over $800 Million to Montgomery County Expansion
Over $800M commitment to Montgomery County expansion. - +9.2 GSK to Expand Operations in Montgomery County, Creating Over 300 New Jobs
Expansion creating over 300 new jobs. - −7.5 AstraZeneca Efzimfotase Alfa Misses Primary Endpoint in HPP Trial
Efzimfotase alfa missed primary endpoint in HPP trial. - +7.0 Convatec (LSE:CTEC) Accelerate Strategy Sets Out a Path to Faster Organic Growth With FTSE 100 in Focus
Company strategy aimed at faster organic growth; constructive framing, limited detail. - +7.0 Smith & Nephew (LSE:SN) Europe Cartilage Implant Launch Strengthens Sports Medicine Growth While FTSE 100 Trades Higher
European cartilage implant launch supports sports medicine growth prospects for the company. - −6.7 AstraZeneca announces ALXN1850 did not achieve statistical significance
Trial of ALXN1850 missed statistical significance. - +6.7 What Is GSK (LSE:GSK) Really Gaining From Its New AI Drug Discovery Deal?
New AI drug discovery deal, questions about gains. - +6.7 That is Roughly $2.7 Million of Investment Per New Job: Welcome to Biologics Manufacturing
Biologics manufacturing investment and jobs, though cost per job noted. - +5.0 AstraZeneca (LSE:AZN) AI Drug Discovery Push Keeps The Undervalued Narrative In Play
AI drug discovery push framed as undervalued narrative. - +5.0 Summit secures $2 billion AstraZeneca investment
Large $2 billion investment in Summit supports oncology pipeline. - +4.2 Weekly Recap: U.S. $50B expansion and Summit stake funding ivonescimab
US expansion and Summit stake funding ivonescimab development.
Pharma and healthcare: every day · FTSE 100 overview for the day